Pyrazinamide Resistance and
 pncA
 Gene Mutations in
 Mycobacterium tuberculosis

Juréen, Pontus; Werngren, Jim; Toro, Juan-Carlos; Hoffner, Sven

doi:10.1128/aac.00110-08

Cited by 131 publications

(97 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, in our study 40% of the clinical isolates showed substitutions in rpsL gene but no alteration was found in rrs gene. Jureen et al in their study from Sweden observed many mutations for pncA gene [26], and in 2009, S S Prabhu et al from India had found many mutations in pncA gene at various codons [27], but we observed overall 35% frequency of the mutation at codon 195 of pncA gene. Mita et al 2008 from India had found reported and some novel mutation in embB [28].…”

Section: Discussioncontrasting

confidence: 50%

Development of Sequence Based Molecular Diagnostic Test to Evaluate MDR and XDR in M. tuberculosis Patients from Western India

Potdar¹,

Thakur²

2013

AJIDM

View full text Add to dashboard Cite

Globally, Tuberculosis is the most distress disease which remains as a major challenge from the standpoint of diagnosis, detection of drug resistance, and treatment. The increasing knowledge in molecular biology techniques has improved our understanding of the molecular mechanisms of drug resistance for the major first and second-line anti-tubercular drugs. Thus, rapid and accurate diagnosis of Tuberculosis would improve patient care and limit its transmission. This study is aimed to identify mutations in drug resistance genes of first and second line drugs against Mycobacterium tuberculosis by using polymerase chain reaction (PCR) and DNA sequencing methods. This study involves sputum samples of 20 patients diagnosed to have pulmonary tuberculosis. The genomic DNA from clinical isolates was isolated using simple boiling method. PCR amplification and DNA sequencing were performed for katG, inhA, ndh, kasA, pncA, embB, rrs, rpsL, rpoB, gyrA, gyrB and thyA genes. Sequence analysis was done using Bioedit, a bioinformatics tool. The isolates of Mycobacterium tuberculosis from western part of India were analyzed by DNA sequencing revealed total 29 mutations in first line drugs. Out of them, 5(25%) in rpoB at codon 516 and 531, 6(30%) in katG at codon 315, 8(40%) in rpsL at codon 43 & 88, 3(15%) in embB at codon 306 and 7(35%) in pncA at codon 195.No mutations in inhA, ndh, kasA and rrs genes were observed in our study. In the second line drugs, 2(10%) at codon 90 & 100% mutations at codon 95 in gyrA gene, and no mutation in gyrB and thyA genes were observed.

show abstract

Section: Discussioncontrasting

confidence: 50%

Development of Sequence Based Molecular Diagnostic Test to Evaluate MDR and XDR in M. tuberculosis Patients from Western India

Potdar¹,

Thakur²

2013

AJIDM

View full text Add to dashboard Cite

show abstract

“…Pyrazinamide is a prodrug that converted to pyrazinoic acid by the enzyme pyrazinamidase, encoded by the pncA gene in Mycobacterium strains. Mutations in pncA results to lost or reduced pyrazinamidase activity which leads to development of resistance [23]. In this experiment, after biofield treatment pyrazinamide reduced 31.4% resistance property in XDR strains besides increased susceptibility by four folds in case of MDR strains as compared to control ( Table 1).…”

Section: Citationmentioning

confidence: 80%

An Impact of Biofield Treatment: Antimycobacterial Susceptibility Potential Using BACTEC 460/MGIT-TB System

Trivedi¹,

Patil²,

Shettigar³

et al. 2015

Mycobact Dis

View full text Add to dashboard Cite

The aim was to evaluate the impact of biofield treatment modality on mycobacterial strains in relation to antimycobacterials susceptibility. Mycobacterial sensitivity was analysed using 12 B BACTEC vials on the BACTEC 460 TB machine in 39 lab isolates (sputum samples) from stored stock cultures. Two American Type Culture Collection (ATCC) strains were also used to assess the minimum inhibitory concentration (MIC) of antimicrobials (Mycobacterium smegmatis 14468 and Mycobacterium tuberculosis 25177). Rifampicin, ethambutol and streptomycin in treated samples showed increased susceptibility as 3.33%, 3.33% and 400.6%, respectively, as compared to control in extensive drug resistance (XDR) strains. Pyrazinamide showed 300% susceptibility as compared to control in multidrug resistance (MDR) strains. Isoniazide did not show any improvement of susceptibility pattern against treated either in XDR or MDR strains of Mycobacterium as compared to control. Besides susceptibility, the resistance pattern of treated group was reduced in case of isoniazide (26.7%), rifampicin (27.6%), pyrazinamide (31.4%), ethambutol (33.43%) and streptomycin (41.3%) as compared to the untreated group of XDR strains. The MIC values of few antimicrobials were also altered in the treated group of Mycobacterium smegmatis. There was a significant reduction observed in MIC values of linezolid (8.0 to 2.0 µg/ml) and tobramycin (2.0 to 1.0 µg/ml); however, very slight changes occurred in the remaining antimicrobials of treated samples. There was no change of MIC values in the strain of Mycobacterium tuberculosis after biofield treatment. Biofield treatment effect on Mycobacterium against anti-tubercular drugs might be due to altered ligand-receptor/protein interactions at either enzymatic and/or genetic level with respect to anti-mycobacterium susceptibility and MIC values of antimicrobials.

show abstract

“…A comparable situation is found in the case of the resistance to PZA, another pro-drug which has pcnA as its activator. Mutations in this gene, encoding the amidase required to produce the active drug, Pyrazinoic acid (POA), accounts for a large fraction of the resistance in M. tuberculosis (Jureen et al, 2008). In spite of that, PZA resistant strains without mutation in pcnA have been reported (Raynaud et al, 1999).…”

Section: Efflux Pumps In M Tuberculosis Their Role In Tolerance To mentioning

confidence: 99%

In Search of El Dorado: Current Trends and Strategies in the Development of Novel Anti-Tubercular Drugs

Morbidoni¹

2012

Understanding Tuberculosis - New Approaches to Fighting Against Drug Resistance

View full text Add to dashboard Cite

Pyrazinamide Resistance and pncA Gene Mutations in Mycobacterium tuberculosis

Cited by 131 publications

References 22 publications

Development of Sequence Based Molecular Diagnostic Test to Evaluate MDR and XDR in <i>M.</i> <i>t</i><i>uberculosis</i> Patients from Western India

Development of Sequence Based Molecular Diagnostic Test to Evaluate MDR and XDR in <i>M.</i> <i>t</i><i>uberculosis</i> Patients from Western India

An Impact of Biofield Treatment: Antimycobacterial Susceptibility Potential Using BACTEC 460/MGIT-TB System

In Search of El Dorado: Current Trends and Strategies in the Development of Novel Anti-Tubercular Drugs

Contact Info

Product

Resources

About